China is a high-incidence country for hepatocellular carcinoma (HCC), with consistently high rates of both morbidity and mortality. The majority of HCC patients are already in the advanced stages at the time of diagnosis, losing the opportunity for surgery. Combined targeted therapy and immunotherapy (targeted-immune combination) and targeted-immune combination local therapy have become the hot topic in the treatment of advanced-stage HCC in recent years. Combination therapy based on immune checkpoint inhibitors has significantly improved the efficacy for patients with advanced-stage HCC. However, there is a significant difference in treatment plans and experiences among different medical institutions, lacking a unified consensus and a model for comprehensive management as a reference. Recently, the Hepatic Oncology Branch and Immunology Branch of China International Exchange and Promotive Association for Medical and Health Care and the Expert Consensus Collaborative Group on Targeted-Immune Combination Local Therapy for Advanced Hepatocellular Carcinoma took the lead in formulating and releasing the Chinese expert consensus on targeted-immune combination local therapy for advanced hepatocellular carcinoma. This consensus provides detailed explanations from various perspectives on the definition of targeted-immune combination local therapy for HCC, the eligible population and management, the selection of treatment methods, strategies for converting unresectable tumors into resectable tumors, treatment strategies for tumor progression, and the management of common adverse reactions. Here, the authors interpret the key points of this consensus and look ahead to how the consensus can adapt to the current background of research or practice.